Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 187

1.

Predictors of adherence with antihypertensive and lipid-lowering therapy.

Chapman RH, Benner JS, Petrilla AA, Tierce JC, Collins SR, Battleman DS, Schwartz JS.

Arch Intern Med. 2005 May 23;165(10):1147-52.

PMID:
15911728
2.

Predictors of adherence to concomitant antihypertensive and lipid-lowering medications in older adults: a retrospective, cohort study.

Chapman RH, Petrilla AA, Benner JS, Schwartz JS, Tang SS.

Drugs Aging. 2008;25(10):885-92.

PMID:
18808213
3.

Does synchronizing initiation of therapy affect adherence to concomitant use of antihypertensive and lipid-lowering therapy?

Agarwal S, Tang SS, Rosenberg N, Pettitt D, McLaughlin T, Joyce A, Schwartz JS.

Am J Ther. 2009 Mar-Apr;16(2):119-26. doi: 10.1097/MJT.0b013e31816b69bc.

PMID:
19114872
4.

[Adherence to antihypertensive and lipid-lowering medications: a problem of public health, not yet resolved].

Grosso G, Raciti T, Marventano S, Romeo I, Mistretta A.

Ann Ig. 2011 Mar-Apr;23(2):173-84. Italian.

PMID:
21770233
5.

Association between prescription burden and medication adherence in patients initiating antihypertensive and lipid-lowering therapy.

Benner JS, Chapman RH, Petrilla AA, Tang SS, Rosenberg N, Schwartz JS.

Am J Health Syst Pharm. 2009 Aug 15;66(16):1471-7. doi: 10.2146/ajhp080238.

PMID:
19667004
6.

Follow-up lipid tests and physician visits are associated with improved adherence to statin therapy.

Benner JS, Tierce JC, Ballantyne CM, Prasad C, Bullano MF, Willey VJ, Erbey J, Sugano DS.

Pharmacoeconomics. 2004;22 Suppl 3:13-23.

PMID:
15669150
7.

Effect of medication burden on persistent use of lipid-lowering drugs among patients with hypertension.

Robertson TA, Cooke CE, Wang J, Shaya FT, Lee HY.

Am J Manag Care. 2008 Nov;14(11):710-6.

8.

Are high-risk hypertensive patients being prescribed concomitant statin therapy?: a retrospective cohort study.

Chapman RH, Petrilla AA, Berman L, Benner JS, Tang SS.

Am J Cardiovasc Drugs. 2009;9(5):299-308. doi: 10.2165/11312110-000000000-00000.

PMID:
19791839
9.

Transition probabilities and predictors of adherence in a California Medicaid population using antihypertensive and lipid-lowering medications.

Nichol MB, Knight TK, Wu J, Tang SS, Cherry SB, Benner JS, Hussein M.

Value Health. 2009 Jun;12(4):544-50. doi: 10.1111/j.1524-4733.2008.00474.x. Epub 2008 Nov 19.

10.

Association between copayment and adherence to statin treatment initiated after coronary heart disease hospitalization: a longitudinal, retrospective, cohort study.

Ye X, Gross CR, Schommer J, Cline R, St Peter WL.

Clin Ther. 2007 Dec;29(12):2748-57. doi: 10.1016/j.clinthera.2007.12.022.

PMID:
18201593
11.

The impact of thiazide diuretics on the initiation of lipid-reducing agents in older people: a population-based analysis.

Monane M, Gurwitz JH, Bohn RL, Glynn RJ, Levin R, Monette J, Avorn J.

J Am Geriatr Soc. 1997 Jan;45(1):71-5.

PMID:
8994491
12.
14.

Association between short-term effectiveness of statins and long-term adherence to lipid-lowering therapy.

Benner JS, Pollack MF, Smith TW, Bullano MF, Willey VJ, Williams SA.

Am J Health Syst Pharm. 2005 Jul 15;62(14):1468-75.

PMID:
15998926
15.

Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients.

Mazzaglia G, Ambrosioni E, Alacqua M, Filippi A, Sessa E, Immordino V, Borghi C, Brignoli O, Caputi AP, Cricelli C, Mantovani LG.

Circulation. 2009 Oct 20;120(16):1598-605. doi: 10.1161/CIRCULATIONAHA.108.830299. Epub 2009 Oct 5.

16.

Predictors of adherence among Alzheimer's disease patients receiving oral therapy.

Borah B, Sacco P, Zarotsky V.

Curr Med Res Opin. 2010 Aug;26(8):1957-65. doi: 10.1185/03007995.2010.493788.

PMID:
20569067
17.

Predictors of failure to initiate randomized treatment in a large trial of antihypertensive drug therapy in the aged.

Nelson MR, Ryan P, Willson K, Reid CM, Beilin LJ, Jennings GL, Johnston CI, Macdonald GJ, Marley JE, McNeil JJ, Morgan TO, West MJ, Wing LM.

Am J Hypertens. 2005 Jun;18(6):885-8.

PMID:
15925752
18.
19.

Impact of adherence to antihypertensive agents on clinical outcomes and hospitalization costs.

Dragomir A, Côté R, Roy L, Blais L, Lalonde L, Bérard A, Perreault S.

Med Care. 2010 May;48(5):418-25. doi: 10.1097/MLR.0b013e3181d567bd.

PMID:
20393367
20.

Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia.

Darkow T, Henk HJ, Thomas SK, Feng W, Baladi JF, Goldberg GA, Hatfield A, Cortes J.

Pharmacoeconomics. 2007;25(6):481-96.

PMID:
17523753

Supplemental Content

Support Center